Similar articles

• [Tumor marker in urology].

  Shimazaki J, Ito H, Miyauchi T, Maruoka M, Isaka S, Masukagami T, Ando K. Shimazaki J, et al. Gan No Rinsho. 1983 May;29(6):684-92. Gan No Rinsho. 1983. PMID: 6192269 Japanese.
• Immunocytochemical evaluation of human prostatic carcinomas for carcinoembryonic antigen, nonspecific cross-reacting antigen, beta-chorionic gonadotrophin, and prostate-specific antigen.

  Purnell DM, Heatfield BM, Trump BF. Purnell DM, et al. Cancer Res. 1984 Jan;44(1):285-92. Cancer Res. 1984. PMID: 6197163
• [Serum levels of alpha fetoprotein (AFP), B-chorionic gonadotropin (BHCG), ferritin and prostatic acid phosphatase (PAP) in patients with cancer of the stomach].

  Bukowski J, Góźdź S, Słuszniak J, Słuszniak A, Korejba W, Zieliński A, Banasińska E. Bukowski J, et al. Wiad Lek. 1988 Jul 15;41(14):915-20. Wiad Lek. 1988. PMID: 2467444 Polish. No abstract available.
• Tumour markers.

  Pandha HS, Waxman J. Pandha HS, et al. QJM. 1995 Apr;88(4):233-41. QJM. 1995. PMID: 7540924 Review.
• [Immunologic aspects in urologic tumors].

  Ackermann R. Ackermann R. Med Klin. 1980 Jun 6;75(12):436-41. Med Klin. 1980. PMID: 6156392 Review. German. No abstract available.